Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 172
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Quarterly Psychedelics Briefing: Q3 2026
Weekly Psychedelic Policy Briefing, September 21, 2026
Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity
Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
Looking Forward to Horizons Northwest, This September in Portland
COMPASS Pathways to participate in three upcoming investor events
Optimi Health Provides Progress Report On Year Of Commercialization
FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN...
Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of...
Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine...
Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment...
Optimi Health Enters Into International Collaborative Research and Supply Agreement With...
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
Load more